| Literature DB >> 28587363 |
Lin-Ru Zeng1, Fang-Bing Zhu1, Jian-Yue Wang1, Qiao Hou1, Zhen-Shuang Yue1, Shi-Gui Yan2, Ren-Fu Quan1, Ying-Liang Zhang1.
Abstract
We studied the effect of molecular polyethylene particles on local heterotopic ossification. A total of 36 healthy Sprague-Dawley rats were randomly divided into the control group (n=18) and the observation group (n=18). High molecular polyethylene particles were injected to rupture Achilles tendon position in the observation group, and normal saline was injected in the control group. X-ray examinations were conducted on Achilles tendon in the 4th, 8th and 12th week after operation. The incidence rate of heterotopic ossification was evaluated, and bone trabecula morphological structure was studied under optical microscope after hematoxylin and eosin staining. Bone morphogenetic protein 2 (BMP-2), transforming growth factor-β (TGF-β), interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), runt-related transcription factor 2 (Runx2) and matrix metalloproteinase-9 (MMP-9) expression levels were also measured. Our results showed that heterotopic ossification incidence in the observation group was significantly lower than that in the control group. Achilles tendon structure in the control group increased in volume, and its texture was harder and cartilage-like. In the observation group, trabecular bone volume, thickness and quantity were more than those observed in the control group. BMP-2, TGF-β, IL-1, TNF-α, Runx2 and MMP-9 levels in the observation group were significantly lower than those in the control group. We concluded that, high molecular polyethylene particles had a significant inhibiting effect on local heterotopic ossification.Entities:
Keywords: bone morphogenetic protein 2; bone trabecula; heterotopic ossification; high molecular polyethylene particles; interleukin-1; matrix metalloproteinase-9; runt-related transcription factor 2; transforming growth factor-β; tumor necrosis factor-α
Year: 2017 PMID: 28587363 PMCID: PMC5450723 DOI: 10.3892/etm.2017.4327
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.Incidence rate of heterotopic ossification by X-ray (upper ones are control group, the lower ones are observation group. From left to right: 4, 8 and 12 weeks).
Histological examination comparison.
| Category | Control group | Observation group | t-test | P-value |
|---|---|---|---|---|
| Trabecular bone volume | ||||
| 4th week | 2.2±0.5 | 3.6±0.8 | 5.632 | 0.024 |
| 8th week | 2.3±0.6 | 4.5±1.1 | 6.432 | 0.016 |
| 12th week | 2.4±0.6 | 5.3±1.5 | 7.412 | 0.009 |
| Thickness | ||||
| 4th week | 1.5±0.4 | 1.9±0.6 | 4.236 | 0.032 |
| 8th week | 1.6±0.5 | 2.2±0.8 | 4.958 | 0.025 |
| 12th week | 1.7±0.6 | 2.6±1.2 | 5.237 | 0.021 |
| Quantity | ||||
| 4th week | 2.4±0.9 | 3.0±0.9 | 4.526 | 0.030 |
| 8th week | 2.3±0.8 | 3.5±1.3 | 5.714 | 0.022 |
| 12th week | 2.4±1.0 | 3.9±1.5 | 6.326 | 0.017 |
Inflammatory factor expression quantity comparison.
| Category | Control group | Observation group | t-test | P-value |
|---|---|---|---|---|
| BMP-2 | ||||
| 4th week | 5.6±1.2 | 2.3±0.6 | 5.236 | 0.032 |
| 8th week | 9.4±1.8 | 5.4±0.9 | 6.421 | 0.025 |
| 12th week | 11.5±2.2 | 7.6±1.2 | 7.523 | 0.014 |
| TGF-β | ||||
| 4th week | 3.6±0.8 | 1.2±0.4 | 5.629 | 0.029 |
| 8th week | 7.2±1.3 | 2.3±0.9 | 6.532 | 0.023 |
| 12th week | 9.5±1.9 | 4.6±1.3 | 7.524 | 0.015 |
| IL-1 | ||||
| 4th week | 4.5±1.1 | 2.1±0.7 | 5.236 | 0.033 |
| 8th week | 6.8±1.9 | 3.3±1.1 | 5.895 | 0.026 |
| 12th week | 8.4±2.2 | 5.2±1.6 | 6.632 | 0.023 |
| TNF-α | ||||
| 4th week | 5.6±1.3 | 2.4±0.6 | 5.426 | 0.030 |
| 8th week | 9.4±1.8 | 4.3±1.2 | 6.329 | 0.026 |
| 12th week | 11.7±2.4 | 6.6±1.7 | 7.521 | 0.015 |
| Runx2 | ||||
| 4th week | 3.3±0.6 | 1.2±0.3 | 4.629 | 0.038 |
| 8th week | 7.2±1.4 | 2.3±0.8 | 5.638 | 0.030 |
| 12th week | 9.5±2.3 | 3.4±1.5 | 6.429 | 0.024 |
| MMP-9 | ||||
| 4th week | 6.2±1.3 | 3.2±1.1 | 5.826 | 0.032 |
| 8th week | 9.5±2.4 | 4.5±1.8 | 6.754 | 0.025 |
| 12th week | 11.9±3.2 | 6.7±2.4 | 7.895 | 0.013 |
BMP-2, bone morphogenetic protein 2; TGF-β, transforming growth factor-β; IL-1, interleukin-1; TNF-α, tumor necrosis factor-α; Runx2, runt-related transcription factor 2; MMP-9, matrix metalloproteinase-9.